The new deal will position medical device giant Boston Scientific as Preventice’s exclusive sales and marketing representative for its cardiology-related diagnostic and monitoring offerings, the companies said.
“This agreement marks an important strategic milestone for Preventice Solutions. We are thrilled to partner with Boston Scientific and collaborate on additional areas of mutual commercial and strategic interest,” Preventice president Jon Otterstatter said in a prepared statement.
The market for cardiac monitoring is greater than $1 billion, the companies said, and is growing to include wearable monitors as well as implantable or insertable monitors.
“By partnering with Boston Scientific, we will expand our service capability and build a foundation for a future in the management of remote patient care,” Preventice COO John Untereker said in a press release.
Last year, Preventice joined with remote cardiac monitoring devices maker eCardio Diagnostics under a new holding company, Preventice Inc.
The new company combined Preventice’s commercially available wireless remote cardiac monitoring systems with eCardio’s national sales force and patient monitoring center.